FANG Lianhua
Principal Investigator
Fang Lianhua's main research field is cardiovascular pharmacology and R&D of innovative drug. Her research focus is on the identification of drug targets, the research of screening techniques for high-throughput screening, especially further evaluation and mechanism research of active compounds, including the research of intracellular signal transduction pathways related to vascular function and drug intervention, as well as the R&D of innovative drugs for the pulmonary hypertension, hypertension and diabetic vascular disease, etc.
Fang has presided over a number of national projects, and published more than 130 papers. She has been granted 14 patents, edited 2 monographs as associate editor and 18 monographs as co-editor. She has won many scientific research honors.
1. Xiao-Xu-Ming Decoction regulates vascular function by modulating G Protein-Coupled Receptors: a molecular docking study. BioMed Res Int, 2021, 2021: 5575443.
2. Systematic analysis of molecular mechanism of resveratrol for treating pulmonary hypertension based on network pharmacology technology. Eur J Pharmacol, 2020, 888, 173466.
3. Puerarin attenuates the endothelial-mesenchymal transition induced by oxidative stress in human coronary artery endothelial cells through PI3K/AKT pathway. Eur J Pharmacol, 2020 Nov, 886, 173472.
4. Coptisine alleviates pristane-induced lupus-like disease and associated kidney and cardiovascular complications in mice. Front Pharmacol, 2020 June, 11: 00929.
5. Total flavonoids from Anchusa italica Retz. improve cardiac function and attenuate cardiac remodeling post myocardial infarction in mice. J Ethnopharmacol, 2020, July, 257: 112887.
6. Systematic elucidation of the mechanism of genistein against pulmonary hypertension via network pharmacology approach. Int J Mol Sci, 2019, Nov; 20(22): E5569.
7. Puerarin protects pulmonary arteries from hypoxic injury through the BMPRII and PPARγ signaling pathways in endothelial cells. Pharmacol Rep, 2019 Oct, 71(5): 855-861.
8. A novel hypertensive crisis rat model established by excessive norepinephrine infusion and the potential therapeutic effects of Rho-kinase inhibitors on it. Biomed Pharmacother, 2019 Jan, 109:1867-1875.
9. Cardioprotective effects of Puerarin-V on isoproterenol-induced myocardial infarction mice is associated with regulation of PPAR-γ/NF-κB pathway. Molecules, 2018, 23(12), 3322.
10. Vasorelaxant effect of quercetin on cerebral basilar artery in vitro and the underlying mechanisms study. J Asian Nat Prod Res, 2018 May; 20(5):477-487.
11. Salvianolic acid A alleviates renal injury against the systemic lupus erythematosus induced by pristane in BALB/c mice. Acta Pharm Sin B. 2017 Mar; 7(2): 159-166.
12. Activation of Nrf2 attenuates pulmonary vascular remodeling via inhibiting endothelial-to-mesenchymal transition: An insight from a plant polyphenol. Int J Biol Sci, 2017 Sep, 13(8): 1067-1081.
13. Salvianolic acid A, a component of Salvia Miltiorrhiza, attenuates endothelial-mesenchymal transition of HPAECs induced by hypoxia. Am J Chin Med, 2017; 45(6):1185-1200.
14. The Protective Effect of DL0805 derivatives on pulmonary artery cells and the underlying mechanisms study. Current Vasc Pharmacol. 2017 Jul: 15(5): 469-476
15. Pharmacokinetics and tissue distribution of coptisine in rats after oral administration by liquid chromatography-mass spectrometry. Biomed Chromatogr. 2017 Jul; 31(7): e3918.
16. Fasudil evokes vasodilatation of rat mesenteric vascular bed via Ca2+ channels and Rho/ROCK pathway. Eur J Pharmacol. 2016, Oct; 788: 226-233.
17. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model. Acta Pharmacol Sin. 2016, 37(6): 772-782.
18. DL0805-2, a novel indazole derivative, relaxes Angiotensin II-induced contractions of rat aortic rings by inhibiting Rho kinase and calcium fluxes. Acta Pharmacol Sin. 2016, 37(5): 604-616.
19. Brazilin isolated from the heartwood of Caesalpinia sappan L induces endothelium- dependent and independent relaxation of rat aortic rings. Acta Pharmacol Sin, 2015 Oct; 36(11): 1318-1326.
20. Vasodilatory effect of a novel Rho-kinase inhibitor, DL0805-2, on the rat mesenteric artery and its potential mechanisms. Cardiovasc Drugs Ther, 2014 Oct; 28(5): 415-424.
1. Experimental Pharmacology (2nd Ed). Chief Editor: Du Guan-hua/Vice Chief Editor: Fang Lian-hua, Wang Jin-hua, Lu Yang, Chen Nai-hong, at al. Edited by Shan Ran-dong and Zhao Jun-yi. Higher Education Press, 2021. ISBN: 978-7-04-054780-1.
2. Overview of ancient and modern research on “toxicity” of Traditional Chinese Medicinal Materials, Chief Editor: Du Guan-hua/Co-edited by Fang Lian-hua, at al. China Medical Science Press, 2019. ISBN: 978-7-5214-0668-9.
3. Natural Small Molecule Drugs from Plants. Chief Editor: Du Guan -hua/Co-edited by Fang Lian-hua, at al. Springer Press, 2019. ISBN: 978-981-10-8022-7.
4. Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th Ed). Chief Editor: Jin You-yu, Li Da-kui/Co-edited by Fang Lian-hua, Wang Shou-bao, Du Guan-hua et al. People's Medical Publishing House, 2016. ISBN: 9787509137444.
5. The chemistry, pharmacology and clinical therapeutic effects of Danshen. Chief Editor: Zhang Jun-tian, Du Guan-hua/Co-edited by Fang Lian-hua, at al. Chemical Industry Press, 2013. ISBN: 9787122174819.
1. 2019. Chinese Medical Science and Technology Award, the second prize. Chinese Medical Association. China.
2. 2017. Chinese Medical Science and Technology Award, the third prize. Chinese Medical Association. China.
3. 2011. Chinese Medical Science and Technology Award, the third prize. Chinese Medical Association. China.
4. 2009. Beijing Science and Technology Award, the second prize. People's Government of Beijing Municipality. China.
